Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by Adage Capital Partners GP L.L.C.

Adage Capital Partners GP L.L.C. reduced its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 18.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 650,000 shares of the company’s stock after selling 150,000 shares during the period. Adage Capital Partners GP L.L.C. owned approximately 1.33% of Enliven Therapeutics worth $14,625,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Barclays PLC lifted its position in shares of Enliven Therapeutics by 295.8% during the 3rd quarter. Barclays PLC now owns 56,217 shares of the company’s stock valued at $1,435,000 after acquiring an additional 42,012 shares during the period. Geode Capital Management LLC lifted its stake in shares of Enliven Therapeutics by 9.9% during the 3rd quarter. Geode Capital Management LLC now owns 750,208 shares of the company’s stock worth $19,164,000 after purchasing an additional 67,813 shares during the period. Franklin Resources Inc. acquired a new stake in shares of Enliven Therapeutics during the third quarter worth $559,000. Lord Abbett & CO. LLC purchased a new stake in shares of Enliven Therapeutics in the third quarter valued at $8,199,000. Finally, SG Americas Securities LLC increased its stake in Enliven Therapeutics by 66.1% in the fourth quarter. SG Americas Securities LLC now owns 16,629 shares of the company’s stock valued at $374,000 after purchasing an additional 6,616 shares during the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright lifted their price target on Enliven Therapeutics from $37.00 to $39.00 and gave the company a “buy” rating in a report on Friday, March 21st.

Enliven Therapeutics Stock Down 0.5 %

ELVN stock opened at $18.21 on Friday. The company has a market cap of $892.36 million, a price-to-earnings ratio of -9.58 and a beta of 1.03. The business has a fifty day simple moving average of $19.37 and a 200-day simple moving average of $22.67. Enliven Therapeutics, Inc. has a 52 week low of $13.30 and a 52 week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.07. The firm had revenue of $0.03 million during the quarter. As a group, analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Enliven Therapeutics

In other news, CFO Benjamin Hohl sold 3,250 shares of the firm’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $21.59, for a total value of $70,167.50. Following the transaction, the chief financial officer now owns 13,000 shares of the company’s stock, valued at approximately $280,670. This trade represents a 20.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Joseph P. Lyssikatos sold 12,500 shares of the company’s stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $20.61, for a total transaction of $257,625.00. Following the sale, the insider now directly owns 1,002,688 shares of the company’s stock, valued at approximately $20,665,399.68. This trade represents a 1.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 66,751 shares of company stock valued at $1,340,713 over the last ninety days. Corporate insiders own 29.20% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.